Skip Nav Destination
1-3 of 3
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL
Clinical Trials & Observations
Jennifer A. Woyach, Farrukh Awan, Ian W. Flinn, Jesus G. Berdeja, Elizabeth Wiley, Sharmeen Mansoor, Ying Huang, Gerard Lozanski, Paul A. Foster, John C. Byrd
Blood (2014) 124 (24): 3553–3560.
Includes: Supplemental data
Dinaciclib (SCH 727965) Is a Novel Cyclin-Dependent Kinase (CDK) Inhibitor That Exhibits Activity In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL)
Joseph M. M. Flynn, DO, MPH, Leslie A. Andritsos, MD, Jeffrey A. Jones, MD, MPH, Amy J. Johnson, PhD, Kami Maddocks, MD, Elizabeth Wiley, Karen Small, BSN, Eun Kyung Im, MD, Michael R. Grever, MD, Rajat Bannerji, MD, PhD, John C. Byrd, MD, Honghong Zhou, PhD
Blood (2013) 122 (21): 871.
Update on the Phase I Study of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity and Feasibility of Long-Term Administration
Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD, MPH, Leslie Andritsos, MD, Kristie A. Blum, MD, Amy J. Johnson, PhD, Josh Hessler, Elizabeth Wiley, Jennifer Poon, PharmD, Karen Small, BSN, Paul Statkevich, PhD, Michael R. Grever, M.D., Rajat Bannerji, MD, PhD, John C. Byrd, MD
Blood (2010) 116 (21): 1396.